@Point of Care
Hematology / Oncology @Point of Care PodcastsEpisodes
Episodes of Hematology / Oncology @Point of Care Podcasts
Mark All
Search Episodes...
Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them.Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE inf
In this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer.Visit www.morningcommutepodcast.com/HER3Agnostic2 to view the activity and CME/CE information, download the transcript, an
In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar.Visit www.morningcommutepodcast.com/HER3Agnostic1 to view t
In this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer.Visit www.morningcommutepodcast.com/HRPositiveBreast3 to view the activity and CME/CE information, download the transc
In this podcast, our faculty take a look at some of the clinical data behind the newer treatment strategies for HR-positive breast cancer as well as how to address and manage some associated adverse events.Visit www.morningcommutepodcast.com/H
In this podcast, our faculty discuss some newer treatment approaches for patients with HR-positive breast cancer including PI3K inhibition, AKT inhibition, and oral selective estrogen receptor down regulators.Visit www.morningcommutepodcast.co
FLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how they are used in AML, and how to manage any treatment-related adverse events.Visit www.morningco
The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the trans
In this podcast our faculty discuss the latest treatment options for AML that target FLT3 mutations: midostaurin, gilteritinib, and the new kid on the block, quizartinib.Visit www.morningcommutepodcast.com/aml2 to view the activity and CME/CE
Our faculty discuss the importance of biomarker testing for FLT3 and FLT3-ITD and the prognostic impact for these patients, especially now that there are therapies targeting these mutations.Visit www.morningcommutepodcast.com/aml1 to view the
In this podcast of our three-part series, our faculty continue their discussion on the treatment of endometrial cancer, this time looking at some of the key data on combination therapies as well as associated adverse events and how to handle th
In this episode of our three-part series on endometrial cancer, our faculty continue their discussion by turning to some of the ongoing, and some may say groundbreaking, clinical trials for the use of immunotherapies in the first-line setting.
In this podcast, our faculty discuss the heterogeneity of endometrial cancer and its four molecular classifications. How do these classifications help determine patient treatment plans?Visit www.MorningCommutePodcast.com/Endometrial3 to view t
In this final podcast of our 3-part series, our faculty take their discussion of metastatic colorectal cancer and HER2-targeted therapies to the clinical level and share some patient cases. You don't want to miss these clinical pearls. Visit
In this podcast, our faculty discuss HER2-positive colorectal cancer. HER2 has long been associated as a biomarker and treatment target for breast cancer, but now it is also a target in some colorectal cancers. Dr. John Marshall and Dr. Sunni K
In this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guideline recommendations for biomarker testing in colorectal cancer? Visit http://www.MorningCo
In this final podcast of our 3-part series, our faculty continue their discussion on multicancer early detection tests, this time turning to how to incorporate these tests into clinical practice. Visit http://www.MorningCommutePodcast.com/Can
In the second episode of our podcast series on early cancer detection, our faculty take a closer look at multicancer early detection tests and the groundbreaking PATHFINDER study that so far is showing impressive data.Visit http://www.MorningC
In this podcast, our faculty discuss new methods of detecting cancer, including liquid biopsy and blood based, multicancer early detection tests. Can one blood sample provide accurate screening for many cancers?Visit http://www.MorningCommuteP
In this final podcast of our three-part series, our faculty look at some of the latest findings on PARP inhibitors as well as what is on the horizon. They also tackle the topic of disparities in care for patients with ovarian cancer and how cli
In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes?Visit http://www.Morn
What is the history behind the development of PARP inhibitors for the treatment of ovarian cancer and how have they influenced recent guideline changes regarding their use? Our faculty discuss this and more in the first podcast of the three-par
In the final episode of our series, our faculty discuss the changing treatment landscape for diffuse large B-cell lymphoma. With more and more options, the paradigm is shifting and that's good news.Visit http://www.MorningCommutePodcast.com/BC
What are the antibody-drug conjugate treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma? In this podcast our faculty look at key trial data as well as treatment management for this disease.Visit http://www
In this podcast, our faculty discuss relapsed/refractory diffuse large B-cell lymphoma, how refractory disease is defined, and the role of the new antibody-based therapies in relapsed/refractory disease.Visit http://www.MorningCommutePodcast.c
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us